Blastic plasmacytoid dendritic cell neoplasm (BPDCN) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Blastic plasmacytoid dendritic cell neoplasm(BPDCN) is a clinically aggressive tumor derived from the precursors of plasmacytoid dendritic cells (PDCs, also called professional type 1 interferon-producing cells or plasmacytoid monocytes), with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination.

According to Thelansis, BPDCN more often affects males (male-to-female ratio = 3.3:1) in the seventh or eighth decade of life, although it can occur at any age, including childhood.

Competitive landscape of BPDCN includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of BPDCN across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

BPDCN Market Forecasting: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. No        Asset        Company           Partner            Stage

1        Elzonris        Stemline Therapeutics, Inc.        NA        Approved

2        IMGN632        ImmunoGen, Inc.        Jazz Pharmaceuticals        I

3        MB-102        Mustang Bio        Fortress Biotech, Inc.        I

4        Venetoclax        Abbvie        Dana-Farber Cancer Institute        I

5        Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes        Mustang Bio, Inc.        NA        I

6        TM123        Cellex Patient Treatment GmbH        PHARMALOG Institut für klinische Forschung GmbH        I

7        UniCAR02-T        Cellex Patient Treatment GmbH        PHARMALOG Institut für klinische Forschung GmbH        I

8        XmAb14045        Xencor, Inc.        ICON Clinical Research        I